ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 676

Cluster Profiling of Patients in a Real-World Data Set with Systemic Lupus Erythematosus and Their Associated Treatments

Zahi Touma1, Benjamin Hoskin 2, Christian Atkinson 2, David Bell 2, Olivia Massey 3, Jennifer Lofland 4, Pamela Berry 5, Chetan Karyekar 6 and Karen Costenbader 7, 1University Health Network, University of Toronto, Toronto, ON, Canada, 2Adelphi Real World, Cheshire, United Kingdom, 3Adelphi Real World, Bollington, United Kingdom, 4Janssen Scientific Affairs, LLC, Spring House, PA, 5Janssen Scientific Affairs, LLC, Horsham, PA, 6Janssen Global Services, LLC, Horsham, PA, 7Brigham and Women's Hospital, Boston, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: cluster, Lupus, profile and Biologics

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Previous systemic lupus erythematosus (SLE) studies have identified potential clusters of SLE clinical manifestations. 

To describe the presentation of SLE across different cohorts of patients and describe standard of care within clusters.

Methods: Cross-sectional study of 263 rheumatologists in the US and EU5. Data were collected from the Adelphi Real World 2015 Lupus Disease Specific Programme. Physicians completed patient record forms (PRFs) for the next 5 patients consulting with SLE; these patients completed patient self-completion (PSC) forms describing how SLE affected them. PRFs data include patient’s characteristics and management history. PSCs focused on similar data collection, including patient reported outcome measures on the humanistic burden.  Principal-component factor analysis reduced 39 unique SLE symptoms to 8 factors. These factors were used as covariates in latent class cluster analysis to provide discrete cohorts of patients. Chi-squared and Kruskal-Wallis tests compared patient outcomes across clusters.

Results: Data were extracted from 1376 PRFs. Factor analysis resulted in 8 clusters of concurrent symptoms; joint, haematological, constitutional/mental health, skin, circulatory, cardiovascular, renal, and muscular symptoms respectively. The four-cluster solution was selected. Cluster 1 displayed the lowest symptom burden, characterised by low skin involvement. Cluster 2 is characterised by joint and skin involvement. Cluster 3 & 4 had a high frequency of all factors, with cardiovascular involvement high in cluster 3 and renal/constitutional involvement high in cluster 4 (table 1). Significant between-cluster differences were observed when comparing clinical and humanistic outcomes; physician/patient satisfaction were greatest in cluster 1 (physician satisfied 94.2% vs. 2: 90.8%, 3: 85.2%, 4: 74.4%, p< 0.0001; patient 94.7% vs. 2: 93.9%, 3: 91.5%, 4: 79.2%, p< 0.0001), whilst disease progression (deteriorating slowly 2.5% vs. 2: 12.9%, 3: 9.8%, 4: 25.5%, p< 0.0001) and flaring in the last 12 months (flared 30.0% vs. 2: 54.8%, 3: 62.2%, 4: 70.8%, p< 0.0001) differed significantly with worst outcomes seen in cluster 4. Significant differences were also observed between clusters in relation to treatment proportions; anti-malarials (highest cluster 1: 70.5%), biologic DMARD (highest cluster 3: 17.5%), glucocorticoid and immunosuppressants (highest cluster 4: 85.5%, 74.5%).

Conclusion: This study adds to the evidence demonstrating the heterogenous nature of SLE experienced within distinct patient clusters. Significant proportions of SLE patients experience high symptom burden and low levels of satisfaction. Additional analysis to understand limited biologic use in more severe patients is needed.

Table 1 Cluster analysis


Disclosure: Z. Touma, Janssen Research & Development, LLC, 2, Janssen Scientific Affairs, LLC, 2; B. Hoskin, Janssen Scientific Affairs, LLC, 5; C. Atkinson, Janssen Scientific Affairs, LLC, 5; D. Bell, Janssen Scientific Affairs, LLC, 5; O. Massey, Adelphi Real World, 3, Janssen Scientific Affairs, LLC, 5; J. Lofland, Janssen Scientific Affairs, LLC, 3; P. Berry, Janssen Scientific Affairs, LLC, 3; C. Karyekar, Abbott, 3, BMS, 3, Janssen, 1, 3, Janssen Scientific Affairs, LLC, 3, Novartis, 3; K. Costenbader, Astra-Zeneca, 2, Glaxo Smith Kline, 2, Janssen Scientific Affairs, LLC, 2, Lupus Foundation of America, 2, Lupus Research Alliance, 2, Merck, 2.

To cite this abstract in AMA style:

Touma Z, Hoskin B, Atkinson C, Bell D, Massey O, Lofland J, Berry P, Karyekar C, Costenbader K. Cluster Profiling of Patients in a Real-World Data Set with Systemic Lupus Erythematosus and Their Associated Treatments [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/cluster-profiling-of-patients-in-a-real-world-data-set-with-systemic-lupus-erythematosus-and-their-associated-treatments/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cluster-profiling-of-patients-in-a-real-world-data-set-with-systemic-lupus-erythematosus-and-their-associated-treatments/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology